Lavo Life Sciences is a startup that offers computer simulations using AI to predict crystal structures of drug molecules at a large scale. With the help of their software, pharmaceutical companies can quickly analyze drug behavior at the atomic level and bring therapies to patients faster. The team of chemists and engineers at Lavo Life Sciences has designed novel techniques to address industry challenges and lower costs for pharmaceutical property prediction. Through their AI-accelerated chemistry simulations, Lavo Life Sciences aims to make drug development faster and more efficient than existing solutions. As they are a venture capital-backed, early-stage startup, Lavo Life Sciences is keen to work with pharmaceutical companies and other relevant partners to help accelerate drug development efforts. In summary, Lavo Life Sciences provides software tools that simulate drugs’ behavior and predict crystal structures, allowing pharmaceutical companies to bring therapies to patients faster and at a lower cost. Their AI-powered simulations are designed to make drug development more efficient by avoiding expensive and time-consuming experiments.
